Previous 10 | Next 10 |
Personalis (NASDAQ: PSNL ): Q3 GAAP EPS of -$0.22 beats by $0.02 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Highlights Record revenues of $17.2 million in the third quarter of 2019, versus $11.7 million in the thir...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of Personalis’ Cancer Whole Genome Sequencing which further extends Personalis’ portfolio of comprehensive cancer genomics services designed to maximize biological insights from...
Now is a great time to have biotech stocks in your portfolio. While biotech investing can be scary, because the small-cap companies are often unprofitable research-and-development labs, this is also where a lot of the cutting-edge science is happening. Let's see how Mirati Therapeutics (NA...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD, November 7-10, including poster presentations on November 8 th and 9 th . ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its third quarter 2019 financial results after the market closes on Wednesday, November 13, 2019. In conjunction with the release, the Company will host a conference call and...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 in Boston, October 27-30, including a poster presentation on October 27...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress USA 2019 in San Diego on October 8 th at 2:50 PM PDT. The presentation , titled “Advancing Precision Oncology Biomarker...
Thanks to a handful of initial public offerings (IPOs) in the last year, individual investors can now own liquid biopsy stocks. Thanks to awful performance last month, most of them are trading at their lowest levels in months -- or ever. Shares of Adaptive Biotechnologies (NASDAQ: ADPT) f...
Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate virtually at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 13, 2024. About Personalis, Inc. At Personalis, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...